• Nuclear Medicine - University College Hospital, Ibadan.

    Lutetium-177 PSMA Therapy Referral Form
  • Lutetium-177 PSMA therapy is a targeted radiopharaceutical treatment for advanced prostate cancer, specifically designed for patients with metastatic castration-resistant prostate cancer (mCRPC) who have limited treatment options. This innovative therapy works by targeting and destroying cancer cells while minimizing harm to healthy tissue. By doing so, it can help reduce symptoms and improve quality of life. Additionally, Lutetium-177 PSMA therapy can also slow disease progression and improve survival rates.
  • Format: (0000) 000-0000.
  • Date of diagnosis*
     - -
    2 digit day, 2 digit month, 4 digit year
  • Bilateral Orchidectomy*
  • Date
     - -
    2 digit day, 2 digit month, 4 digit year
  • Chemotherapy*
  • Docetaxel
  • Start date
     - -
    2 digit day, 2 digit month, 4 digit year
  • End date
     - -
    2 digit month, 2 digit day, 4 digit year
  • Carbazitaxel
  • Start date
     - -
    2 digit day, 2 digit month, 4 digit year
  • End date
     - -
    2 digit month, 2 digit day, 4 digit year
  • Radiotherapy*
  • Castrate Resistant*
  • Date
     - -
    2 digit day, 2 digit month, 4 digit year
  • Any PSMA Scans done ? (Ga-68 PSMA/F-18 PSMA PET or Tc-99m PSMA SPECT)*
  • Date
     - -
    2 digit day, 2 digit month, 4 digit year
  • Browse Files
    Drag and drop files here
    Choose a file
    Cancelof
  • Should be Empty: